作者
Michael D Murray, Melissa M Deer, Jeffrey A Ferguson, Paul R Dexter, Susan J Bennett, Susan M Perkins, Faye E Smith, Kathleen A Lane, Laurie D Adams, William M Tierney, D Craig Brater
发表日期
2001/11/1
期刊
The American journal of medicine
卷号
111
期号
7
页码范围
513-520
出版商
Elsevier
简介
PURPOSE
Because the bioavailability of oral furosemide is erratic and often incomplete, we tested the hypothesis that patients with heart failure who were treated with torsemide, a predictably absorbed diuretic, would have more favorable clinical outcomes than would those treated with furosemide.
PATIENTS AND METHODS
We conducted an open-label trial of 234 patients with chronic heart failure (mean [± SD] age, 64 ± 11 years) from an urban public health care system. Patients received oral torsemide (n = 113) or furosemide (n = 121) for 1 year. The primary endpoint was readmission to the hospital for heart failure. Secondary endpoints included readmission for all cardiovascular causes and for all causes, numbers of hospital days, and health-related quality of life.
RESULTS
Compared with furosemide-treated patients, torsemide-treated patients were less likely to need readmission for heart failure (39 [32 …
引用总数
学术搜索中的文章
MD Murray, MM Deer, JA Ferguson, PR Dexter… - The American journal of medicine, 2001